Latest Breaking News On - Bacillus calmette gue - Page 1 : comparemela.com

Protara Therapeutics Announces Positive Three-Month Data From TARA-002 Clinical Program In NMIBC

Royalty Pharma and Ferring Pharmaceuticals Enter Into US $500 Million Royalty Agreement for New Intravesical Gene Therapy Adstiladrin® (Nadofaragene Firadenovec-Vncg)

Royalty Pharma and Ferring Pharmaceuticals Enter Into US $500 Million Royalty Agreement for New ...

Royalty Pharma to pay Ferring $300 million upfront and a potential $200 million milestone payment in exchange for royalties on the sales of Ferring’s intravesical gene therapy Adstiladrin® (nadofaragene firadenovec-vncg)Transaction

FDA Approves First Gene Therapy for the Treatment of High-Risk, Non-Muscle-Invasive Bladder Cancer

Today, the U.S.

University of Helsinki sold cancer and infectious disease vaccination platform called PeptiBAC to Valo Therapeutics

Potential for regional tuberculosis vaccines, novel personalized cancer vaccines, and improving checkpoint inhibition therapy University of Helsinki and a spinout-company from the University of Helsinki, Valo Therapeutics Limited (Valo Tx) , announced today that Valo Tx acquires the intellectual property rights for the proprietary ´PeptiBAC´technology from the University of Helsinki, Finland. Valo Tx is the developer of novel, adaptable immunotherapy platforms for cancer and infectious diseases. University of Helsinki owns 21% of Valo Tx. PeptiBAC uses the BCG (Bacillus Calmette-Guèrin) vaccine as a backbone for delivery of disease specific peptides. The technology has preventative potential in infectious diseases, specifically tuberculosis (TB, caused by Mycobacterium tuberculosis (MTB)), as well therapeutic potential in cancer. The BGC vaccine, one of the earliest immunotherapies, has been widely used globally for decades. It is safe and well tolerated, with over 10